Procedural Advantages of a Novel Drug-Eluting Coronary Stent

Not Applicable

Completed

• Conditions: Coronary Artery Disease
• Interventions: Device: Currently common drug-eluting stent (DES); Device: Synergy Stent

• Registration Number: NCT02881216
• Lead Sponsor: University Hospital Heidelberg

Brief Summary

This study sought to compare procedural performance of a new coronary stent generation, that is already available in Germany, with hitherto established current drug-eluting stents.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-01
• Primary Completion: 2015-12
• Study Completion: 2016-06
• Status Verified: 2016-08
• Study First Submitted: 2016-08-15
• Study First Submitted QC: 2016-08-23
• Last Update Submitted: 2016-08-25
• Study First Posted: 2016-08-26
• Last Update Posted: 2016-08-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 814

Inclusion Criteria

• CAD for PCI, consecutive patients

Exclusion Criteria

• Age under 18
• Bare Metal Stents or Scaffolds

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Common DES	Currently common drug-eluting stent (DES)	Group of Patients with narrowed coronary artery disease, who were treated with an implantation of currently established drug-eluting stents (Xience Prime, Promus Element plus, Resolute Integrity).
Synergy Stent	Synergy Stent	Group of Patients with narrowed coronary artery disease, who were treated with Synergy stent implantation

Primary Outcome Measures

Name	Time	Method
In-hospital major cardiac adverse events	One week post-procedure	In-hospital major cardiac adverse events were collected up to one week after procedure throughout the in-patients stay